Experience with early use of certolizumab pegol in able-bodied patients with axial spondyloarthritis in the framework of a model for clinical statistical groups
Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease that affects predominantly the sacroiliac joints and spine. The main goal of axSpA therapy is to slow down and prevent structural damages that become a main cause of disability in able-bodied patients. Timely diagnosis and ea...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2020-09-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1056 |
| Summary: | Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease that affects predominantly the sacroiliac joints and spine. The main goal of axSpA therapy is to slow down and prevent structural damages that become a main cause of disability in able-bodied patients. Timely diagnosis and early prescription of biological agents can slow down the progression of the disease. The paper presents the experience in using the tumor necrosis factor-α inhibitor certolizumab pegol (CP) in a young female patient with early axSpA, who receives the drug within the framework of a model for clinical statistical groups (CSG) in the Kaliningrad Region. The high efficiency of CP and the possibility of using the latter within the CSG tariffs allow the drug to be prescribed for early-stage axSpA. The absence of an Fc-fragment in the molecular structure of CP provides additional opportunities for reproductive-aged female patients who can use the drug during the planning stage, pregnancy, and lactation. |
|---|---|
| ISSN: | 1996-7012 2310-158X |